SCHEMBL30455937

SCHEMBL30455937

CC(C)(C)OC(=O)N1CCC2(CC1)CN(c1ncnc3ccc(CCc4ccccc4)cc13)C2

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KIT P10721 3/20 0.49
▸ PARP1 P09874 5/20 0.44
▸ TLR9 Q9NR96 4/20 0.44
▸ TLR7 Q9NYK1 2/20 0.44
▸ SCD5 Q86SK9 1/20 0.43
▸ SLC2A1 P11166 1/20 0.43
▸ OPRD1 P41143 1/20 0.43
▸ OPRK1 P41145 1/20 0.43
▸ CYP11B2 P19099 1/20 0.42
▸ TNKS O95271 3/20 0.42
▸ TNKS2 Q9H2K2 3/20 0.42
▸ PDGFRB P09619 1/20 0.41
▸ ACHE P22303 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25225988 1.00 KIT (0.49) KITPARP1TLR9TLR7SCD5
SCHEMBL31027420 0.92 KIT (0.44) KITPARP1CYP11B2TNKSTNKS2
SCHEMBL25276663 0.91 KIT (0.45) KITPARP1TLR9TLR7SCD5
SCHEMBL30406053 0.91 KIT (0.51) KITPARP1CYP11B2TNKSTNKS2
SCHEMBL25437390 0.91 KIT (0.51) KITPARP1CYP11B2TNKSTNKS2
SCHEMBL25229702 0.87 AKT1 (0.44) KITPDGFRB
SCHEMBL30405237 0.87 KIT (0.44) KITPARP1SCD5CYP11B2TNKS
SCHEMBL25280892 0.87 KIT (0.44) KITPARP1SCD5CYP11B2TNKS
SCHEMBL25224723 0.86 KIT (0.41) KITPARP1SCD5CYP11B2TNKS
SCHEMBL30405752 0.86 KIT (0.41) KITPARP1SCD5CYP11B2TNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163061-A1 INHIBITORS OF MENIN-MLL INTERACTION BALA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-20250066358-A1 Inhibitors of Menin-MLL Interaction BALA THERAPEUTICS, INC. 2025-02-27 — — US disclosed
EP-4444313-A1 INHIBITORS OF MENIN-MLL INTERACTION Bala Therapeutics, Inc. (US) 2024-10-16 — — EP disclosed
CN-118647378-A Inhibitors of Mei Nen protein interaction with MLL 巴拉疗法公司 2024-09-13 — — CN disclosed
WO-2023107687-A1 INHIBITORS OF MENIN-MLL INTERACTION BALA THERAPEUTICS, INC. (US) 2023-06-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163061-A1 INHIBITORS OF MENIN-MLL INTERACTION MLLT1, MEN1, BMI1 KIT 1067/4885PARP1 330/4885TLR9 3834/4885
US-20250066358-A1 Inhibitors of Menin-MLL Interaction MLLT1, MEN1, BMI1 KIT 1067/4885PARP1 330/4885TLR9 3834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback